New registry study tests antibody drugs for rare nerve disease
NCT ID NCT06885957
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This registry study is tracking 200 people with a rare autoimmune disease called neuromyelitis optica spectrum disorder (NMOSD) who are positive for the AQP4 antibody. Researchers are evaluating how well monoclonal antibody therapies work in real-world settings, focusing on preventing relapses and slowing disability. The study will also look at brain scans and immune markers over time to better understand treatment effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
monoclonal antibody therapy
What this could lead to
If successful, this study could confirm that monoclonal antibody therapies effectively reduce relapse rates and disability progression in people with NMOSD.
What could go wrong
This is an observational registry, not a controlled trial, so results may be influenced by other factors. The study is also limited to a Chinese population, so findings may not apply globally.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NMO SPECTRUM DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••